February 25th, 2013
Selections from Richard Lehman’s Literature Review: February 25th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include extended use of apixaban, dabigatran, warfarin, or placebo in VTE, the 5-year follow-up of the SYNTAX study, and more.
January 22nd, 2013
How Will You PROTECT Your Patients with Nonvalvular Afib?
Eiman Jahangir, MD
For which patients is the Watchman left-atrial appendage closure device a better alternative to warfarin and other anticoagulant medications?
January 17th, 2013
Revisiting Novel Anticoagulants in Atrial Fibrillation
John Ryan, MD and Christian Thomas Ruff, MD, MPH
Two experts discuss the evolving landscape of novel anticoagulants for patients with AF. Do you agree with their perspectives? What questions do you have? What has your experience taught you?
December 12th, 2012
AMPLIFYING Treatment for DVT/PE
John Ryan, MD
John Ryan reviews the latest data and suggests that DVT/PE be managed as a chronic condition. Are you using apixaban in these patients, and how long are you treating them for?
December 10th, 2012
Selections from Richard Lehman’s Literature Review: December 10th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include a comparison of warfarin and new oral anticoagulants for managing AF and VTE, two studies of a monoclonal antibody to PCSK9 in patients with hypercholesterolemia, and more.
December 3rd, 2012
Selections from Richard Lehman’s Literature Review: December 3rd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.
November 27th, 2012
Longer Warfarin Therapy After Bioprosthetic Aortic Valve Replacement May Be Beneficial
Larry Husten, PHD
Three months of warfarin is the usual standard of care following bioprosthetic aortic valve replacement (AVR), although the supporting evidence base for this practice is limited. A new, large registry study published in JAMA suggests that more-prolonged warfarin therapy may be beneficial. Danish researchers identified 4075 patients who underwent bioprosthetic AVR. As expected, warfarin treatment between 30 and […]
November 4th, 2012
ASPIRE: Aspirin an Attractive Alternative After First VTE
Larry Husten, PHD
It is unclear what the best approach is for the long-term treatment of people who have had a first unprovoked episode of venous thromboembolism (VTE). Although warfarin is effective at preventing a recurrence, it is inconvenient and raises the risk for bleeding. Newer anticoagulants have not been tested or approved for this population. The ASPIRE (Aspirin […]
November 2nd, 2012
FDA Investigation Finds No Excess Bleeding Risk for Dabigatran
Larry Husten, PHD
In its latest assessment of a highly controversial issue, the FDA has found no indication that bleeding rates for dabigatran (Pradaxa, Boehringer-Ingelheim) are any higher than the bleeding rates for warfarin. The FDA investigation was in response to the large number of post-marketing reports of bleeding in people taking dabigatran. Click here to for the full FDA […]
October 29th, 2012
Selections from Richard Lehman’s Literature Review: October 29th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include CV risk factors and peripheral artery disease in men, radiofrequency ablation in paroxysmal AF, CPR duration and survival after in-hospital cardiac arrest, an everolimus-eluting stent vs. a bare-metal stent in STEMI, job strain and CHD, and more.
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension